Explainable neural-network analysis nominated GPC6 as a Parkinson disease dopaminergic-neuron marker
An explainable machine-learning workflow applied to four post-mortem midbrain single-nucleus RNA-sequencing datasets identified cell-type-specific gene signatures that distinguished Parkinson disease from control cells across datasets (mean balanced accuracy 0.92) and nominated ten candidate genes. GPC6 emerged as a marker in dopaminergic neurons; rare GPC6 variants were enriched among Parkinson disease cases in analyses spanning three case-control cohorts.
Technology: Explainable neural-network classifiers with LIME feature attribution applied to single-nucleus RNA-sequencing data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: GPC6 emerged as a marker in dopaminergic neurons; rare GPC6 variants were enriched among Parkinson disease cases in analyses spanning three case-control cohorts.
- Still unknown: The expression analysis used post-mortem datasets and the rare-variant association is not a functional perturbation or proof of causality. GPC6 remains a candidate marker/association requiring further validation. The reported balanced accuracy is cell-level classifier performance, not a clinical diagnostic test. Source checked; independent replication beyond the reported cohorts was not assessed.
- AI role: The neural-network classifiers identified cell-type-specific genes important for distinguishing Parkinson disease from control nuclei across four datasets; LIME feature attribution prioritized candidate genes. The researchers then used external rare-variant case-control analyses to validate GPC6 enrichment. The model nominates markers and candidates; it does not establish that GPC6 causes Parkinson disease.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41120302/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 88 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.